Chorioretinal Atrophic Lesions Evolution in Patients with Quiescent Myopic Choroidal Neovascularization Followed for More Than 10 Years

References

• Flitcroft DI, He M, Jonas JB, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20–M30. doi:10.1167/iovs.18-25957
   PubMed Web of Science ®Google Scholar
• Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9–25.e12. doi:10.1016/j.ajo.2013.08.010
   PubMed Web of Science ®Google Scholar
• Tan CS, Sadda SR. Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization. Clin Ophthalmol. 2017;11:1741–1746. doi:10.2147/OPTH.S124518
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110(7):1297–1305. doi:10.1016/S0161-6420(03)00461-5
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2018;63:92–106. doi:10.1016/j.preteyeres.2017.10.005
   PubMed Web of Science ®Google Scholar
• El Matri L, Chebil A, Kort F. Current and emerging treatment options for myopic choroidal neovascularization. Clin Ophthalmol. 2015;9:733–744. doi:10.2147/OPTH.S49437
   PubMedGoogle Scholar
• Farinha CL, Baltar AS, Nunes SG, et al. Progression of myopic maculopathy after treatment of choroidal neovascularization. Ophthalmologica. 2014;231(4):211–220. doi:10.1159/000357290
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology. 2010;117(8):1595–611, 611.e1–4. doi:10.1016/j.ophtha.2009.11.003
   Web of Science ®Google Scholar
• Fang Y, Yokoi T, Nagaoka N, et al. Progression of myopic maculopathy during 18-year follow-up. Ophthalmology. 2018;125(6):863–877. doi:10.1016/j.ophtha.2017.12.005
   PubMed Web of Science ®Google Scholar
• Shen LL, Xie Y, Sun M, et al. Associations of systemic health and medication use with the enlargement rate of geographic atrophy in age-related macular degeneration. Br J Ophthalmol. 2021;107(2):261–266.
   PubMed Web of Science ®Google Scholar
• Sayanagi K, Uematsu S, Hara C, et al. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2019;257(4):749–757. doi:10.1007/s00417-018-04214-w
   PubMed Web of Science ®Google Scholar
• Wang J, Ying GS. Growth rate of geographic atrophy secondary to age-related macular degeneration: a meta-analysis of natural history studies and implications for designing future trials. Ophthal Res. 2021;64(2):205–215. doi:10.1159/000510507
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci. 2021;62(5):5. doi:10.1167/iovs.62.5.5
   PubMed Web of Science ®Google Scholar
• Song D, Hua P, VanderBeek BL, et al. Systemic medication use and the incidence and growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Retina. 2021;41(7):1455–1462. doi:10.1097/IAE.0000000000003075
   PubMed Web of Science ®Google Scholar
• Ma H, Yang F, Ding X-Q. Inhibition of thyroid hormone signaling protects retinal pigment epithelium and photoreceptors from cell death in a mouse model of age-related macular degeneration. Cell Death Dis. 2020;11(1):24. doi:10.1038/s41419-019-2216-7
   PubMed Web of Science ®Google Scholar
• Ma H, Yang F, Ding X-Q. Deficiency of thyroid hormone receptor protects retinal pigment epithelium and photoreceptors from cell death in a mouse model of age-related macular degeneration. Cell Death Dis. 2022;13(3):255. doi:10.1038/s41419-022-04691-2
   PubMed Web of Science ®Google Scholar
• Gopinath B, Liew G, Kifley A, Mitchell P. Thyroid dysfunction and ten-year incidence of age-related macular degeneration. Invest Ophthalmol Visual Sci. 2016;57(13):5273–5277. doi:10.1167/iovs.16-19735
   PubMed Web of Science ®Google Scholar
• Chaker L, Buitendijk GH, Dehghan A, et al. Thyroid function and age-related macular degeneration: a prospective population-based cohort study--the Rotterdam Study. BMC Med. 2015;13(1):94. doi:10.1186/s12916-015-0329-0
   PubMedGoogle Scholar
• Xu Z, Zhang M, Zhang Q, Xu T, Tao L. Thyroid disease is associated with higher age-related macular degeneration risk: results from a meta-analysis of epidemiologic studies. Ophthal Res. 2021;64(5):696–703. doi:10.1159/000515273
   PubMed Web of Science ®Google Scholar
• Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women’s Health Initiative Sight Exam ancillary study. Am J Ophthalmol. 2007;143(3):473–483. doi:10.1016/j.ajo.2006.11.058
   PubMed Web of Science ®Google Scholar
• Chen Y, Han X, Gordon I, et al. A systematic review of clinical practice guidelines for myopic macular degeneration. J Glob Health. 2022;12:04026. doi:10.7189/jogh.12.04026
   PubMed Web of Science ®Google Scholar
• Pece A, Vadalà M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol. 2007;143(3):449–454. doi:10.1016/j.ajo.2006.11.037
   PubMed Web of Science ®Google Scholar
• Pece A, Isola V, Vadalà M, Matranga D. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina. 2006;26(7):746–751. doi:10.1097/01.iae.0000244256.60524.c0
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol. 2011;151(1):137–47.e1. doi:10.1016/j.ajo.2010.06.046
   PubMed Web of Science ®Google Scholar
• Coutinho AM, Silva RM, Nunes SG, Cachulo ML, Figueira JP, Murta JN. Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up. Retina. 2011;31(6):1089–1094. doi:10.1097/IAE.0b013e3181ff9546
   PubMed Web of Science ®Google Scholar
• Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina. 2012;32(8):1547–1552. doi:10.1097/IAE.0b013e3182411cee
   PubMed Web of Science ®Google Scholar
• Schnurrbusch UE, Jochmann C, Wiedemann P, Wolf S. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2005;243(8):829–833. doi:10.1007/s00417-005-1147-4
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003;110(4):667–673.
   PubMed Web of Science ®Google Scholar
• Rishi P, Rishi E, Bhende M, et al. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre. Br J Ophthalmol. 2016;100(10):1337–1340. doi:10.1136/bjophthalmol-2015-307802
   PubMed Web of Science ®Google Scholar
• Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol. 2004;138(5):803–808. doi:10.1016/j.ajo.2004.06.033
   PubMed Web of Science ®Google Scholar
• Airaldi M, Corvi F, Cozzi M, Nittala MG, Staurenghi G, Sadda SR. Differences in long-term progression of atrophy between neovascular and nonneovascular age-related macular degeneration. Ophthalmol Retina. 2022;6(10):914–921. doi:10.1016/j.oret.2022.04.012
   PubMedGoogle Scholar
• Eshtiaghi A, Issa M, Popovic MM, Muni RH, Kertes PJ. Geographic atrophy incidence and progression after intravitreal injections of anti-vascular endothelial growth factor agents for age-related macular degeneration: a meta-analysis. Retina. 2021;41(12):2424–2435. doi:10.1097/IAE.0000000000003207
   PubMed Web of Science ®Google Scholar
• Bae KW, Kim DI, Kim BH, et al. Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. PLoS One. 2022;17(9):e0273613. doi:10.1371/journal.pone.0273613
   PubMed Web of Science ®Google Scholar
• Siedlecki J, Koch C, Schworm B, et al. Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment. BMC Ophthalmol. 2021;21(1):4. doi:10.1186/s12886-020-01766-6
   PubMed Web of Science ®Google Scholar